Register Today to Attend the Virtual PBC Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting on February 4th, 2022!
In collaboration with the PBC community, Global Liver Institute (GLI) is leading the Primary Biliary Cholangitis (PBC) Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) to be held virtually on February 4, 2022 at 10 a.m. ET to 4:30 p.m. ET. A PFDD meeting of this magnitude will allow the U.S. Food and Drug Administration (FDA) and other stakeholders across the medical field to obtain a wide range of patients' and caregivers' input on PBC, including their perspectives on their condition, its impact on daily life, and the urgency around developing therapies.
This EL-PFDD meeting will also provide an opportunity to present critical data gathered from GLI's PBC patient and caregiver survey, along with testimony from a diverse group of patients and caregivers impacted by PBC. The combination of surfaced data from the survey and virtual testimonies will provide clarity on the priorities and preferences for addressing PBC by individuals who have PBC and caregivers of people with PBC.
The EL-PFDD meeting is a critical first step in providing the entire health community with a deeper understanding of PBC. We hope to see you there!
Disclaimer: By completing this form you will be opted-in to receive email from the Global Liver Institute (GLI). You may unsubscribe at any time by either clicking on the appropriate link in the email or contacting us at advocacy@globalliver.org.
